rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Cytosorbents Corporation

CTSO · Nasdaq

Health CareMedical DevicesIn trend

CTSO stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 217.3% above that average now. Medical Devices: 27% of its 181 stocks in an uptrend (−9 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
In trend
Weeks in an uptrend
out for 52
Industry in uptrend
27% -9 in 4 wk
Insider buys, 12 months
$539K
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
48 (+0)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.

17 Apr – 16 Oct
19%29%40%Apr 26Jun 26Jul 26Sep 26Oct 26

Medical Devices: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$287KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months7
Sale orders, 12 months0
Buyers · sellers4 · 0
WhoDidSharesTraded
Alan D. SobelDirectorbought1,900at $6.1215 Sep 2026filed 16 Sep 2026
Alan D. SobelDirectorbought500at $6.0515 Sep 2026filed 16 Sep 2026
Alan D. SobelDirectorbought100at $6.0115 Sep 2026filed 16 Sep 2026
Phillip P. ChanChief Executive Officerbought3,774at $6.0015 Sep 2026filed 16 Sep 2026
Vincent CapponiPresident and COObought1,800at $6.0714 Sep 2026filed 16 Sep 2026
Vincent CapponiPresident and COObought273at $5.9014 Sep 2026filed 16 Sep 2026
Phillip P. ChanChief Executive Officerbought200,000at $0.354 Sep 2026filed 9 Sep 2026
Phillip P. ChanChief Executive Officerbought10,333at $0.4315 Jun 2026filed 15 Jun 2026
Peter J. MarianiChief Financial Officerbought100,000at $0.4415 Jun 2026filed 16 Jun 2026
Phillip P. ChanChief Executive Officerbought251,136at $0.4012 Jun 2026filed 15 Jun 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders48+0 on the quarter
New · exited8 · 7
Reported value$6.0M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
AVENIR CORPreduced · filed 13 Aug 20265,189,218$1.9M-26,558−0.5%
NEUBERGER BERMAN GROUP LLCadded · filed 13 Aug 20261,968,691$741K+285,684+17.0%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20261,914,063$716K+34,074+1.8%
CM Management, LLCunchanged · filed 13 Aug 20261,476,500$552K00.0%
Skylands Capital, LLCreduced · filed 24 Jul 20261,211,400$453K-496,098−29.1%
BlackRock, Inc.reduced · filed 7 Aug 2026627,211$235K-155,781−19.9%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 2026602,059$225K-105,203−14.9%
Sargent Investment Group, LLCadded · filed 11 Aug 2026555,757$208K+5,857+1.1%
Pathstone Holdings, LLCreduced · filed 13 Aug 2026499,910$187K-450.0%
VANGUARD FIDUCIARY TRUST COadded · filed 13 Aug 2026316,167$118K+2,311+0.7%
31 Mar 2023 – 30 Jun 2026
444953Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Alan D. Sobel Company insiderDirector · last 15 Sep 20263 · 0
Phillip P. Chan Company insiderChief Executive Officer · last 15 Sep 202620 · 4
Vincent Capponi Company insiderPresident and COO · last 14 Sep 20266 · 16
Peter J. Mariani Company insiderChief Financial Officer · last 15 Jun 20264 · 0
Edward Raymond Jones Company insiderDirector · last 8 Aug 20253 · 0
Efthymios Deliargyris Company insiderChief Medical Officer · last 8 Aug 20251 · 0
Jiny Kim Company insiderDirector · last 8 Aug 20252 · 0
Michael G. Bator Company insiderDirector · last 8 Aug 20256 · 0
Kathleen P. Bloch Company insiderChief Financial Officer · last 2 Apr 202415 · 11
Al Kraus Company insiderDirector · last 6 Feb 20231 · 52
Eric R. Mortensen Company insiderChief Medical Officer · last 14 Aug 20191 · 0
Robert Hawes Bartlett Company insiderChief Medical Officer · last 24 Feb 20170 · 0

Same industry

RCEL Avita MedicalLeading+100%
ATRC AtriCureLeading+49%
HAE HaemoneticsLeading+48%
HTFL HeartflowLeading+40%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202571.5%
Operating profit marginFY 2025 · to 31 Dec 2025-39.8%
Free cash flow marginFY 2025 · to 31 Dec 2025-33.8%
Return on capital employedFY 2025 · to 31 Dec 2025-42.8%
Debt to equityFY 2025 · to 31 Dec 20252.82×
Share count trendFY 2025 · to 20 Mar 2026-0.2%
Cash and equivalentsFY 2025 · to 31 Dec 2025$6.2M
Free cash flowFY 2025 · to 31 Dec 2025−$12.5M

Analyst forecasts

No analyst forecasts yet.